IDH-Wildtype Glioblastoma
Cross-source consensus on IDH-Wildtype Glioblastoma from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Evidence quality
Where it comes from
Other
Highlighted claims
- The study used newly diagnosed IDH-wildtype glioblastoma under the WHO 2021 classification as its disease definition. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- The curated study cohort contained 176 patients with matched transcriptomic and imaging data. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- IDH-wildtype glioblastoma has an immunosuppressive tumor microenvironment and substantial heterogeneity. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- Immunotherapy has limited proven clinical benefit in IDH-wildtype glioblastoma outside small molecularly defined subgroups. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study